Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Pass Above Fifty Day Moving Average of $5.29

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $5.29 and traded as high as $5.70. Aurinia Pharmaceuticals shares last traded at $5.57, with a volume of 682,487 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on AUPH shares. StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, March 1st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Stock Performance

The stock has a 50-day moving average price of $5.32 and a 200 day moving average price of $6.35. The firm has a market capitalization of $801.75 million, a price-to-earnings ratio of -13.07 and a beta of 1.41. The company has a quick ratio of 5.05, a current ratio of 5.60 and a debt-to-equity ratio of 0.19.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.14. The firm had revenue of $50.30 million during the quarter, compared to the consensus estimate of $46.30 million. Aurinia Pharmaceuticals had a negative net margin of 32.69% and a negative return on equity of 15.06%. On average, analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.15 EPS for the current year.

Institutional Trading of Aurinia Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC purchased a new position in Aurinia Pharmaceuticals during the 4th quarter worth $30,000. Tidemark LLC acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth approximately $39,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Aurinia Pharmaceuticals in the 3rd quarter valued at approximately $65,000. Virtu Financial LLC acquired a new position in shares of Aurinia Pharmaceuticals in the first quarter valued at approximately $78,000. Finally, Eagle Asset Management Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $92,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.